A Japanese research team announced on Friday to implant pluripotent stem cells (iPS) derived from the brain of patients with Parkinson's disease.
Kyoto University researchers injected 2.4 million iPS cells.All types of cells can be generated.– In the left part of the brain during surgery for 3 hours in October.
A man about 50 years old, He has been well cured and will be under surveillance for two years. Kyoto University said in a statement.
If problems occur within the next six months, the researchers will insert 2.4 million additional cells into the right side of the brain.
Healthy donor iPS cells are supposed to develop into neurons that produce dopamine, a neurotransmitter involved in exercise regulation.
Kyoto University announced in July that it will conduct clinical trials with seven people between the ages of 50 and 69.
Parkinson's disease has the following characteristics: There are neuropathies in which symptoms such as tremor, muscle stiffness and loss of athletic ability gradually worsen.
According to the Parkinson 's Disease Foundation, this figure affects more than 10 million people worldwide. Currently available therapies "improve symptoms without slowing the progression of the disease.
The new investigation is to reverse the evil.
In a study published in the scientific journal Nature at the end of August 2017 before clinical trials in humans, experiments were conducted with monkeys with human-derived stem cells that could improve the ability of primates to migrate from Parkinson's disease .
The survival level of the transplanted cells for 2 years was closely monitored by injecting into the primate brain and no tumor was found.
Induced pluripotent stem cells (iPS) produce four genes by virtue of reducing embryonic adult cells to embryonic states (usually inactive in adults). This genetic manipulation returns the ability to produce certain cells depending on where they are implanted.
The use of iPS cells does not cause serious ethical problems unlike stem cells from human embryos.